Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€7.04

€7.04

0.280%
0.02
0.280%
€10.00
 
03.10.24 / Frankfurt WKN: A3C7A5 / Name: Maat Pharma S.a. / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Maat Pharma S.a. Stock

Maat Pharma S.a. gained 0.280% compared to yesterday.
The community is currently still undecided about Maat Pharma S.a. with 1 Buy predictions and 0 Sell predictions.
With a target price of 10 € there is a positive potential of 42.05% for Maat Pharma S.a. compared to the current price of 7.04 €.
So far the community has only identified positive things for Maat Pharma S.a. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of Maat Pharma S.a. in the next few years

Pros
?
S********** s********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

News

MaaT Pharma Publishes its Half Year 2024 Results and Provides a Business Update
MaaT Pharma Publishes its Half Year 2024 Results and Provides a Business Update


Regulatory News:



MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to

MaaT Pharma To Present and Participate in Investor and Medical Conferences in September
MaaT Pharma To Present and Participate in Investor and Medical Conferences in September


Regulatory News:



MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to

MaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
MaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT


Regulatory News:



MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to